# Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

> **NCT02199236** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Rectal or Anal Cancer

## Interventions

- **RADIATION:** endorectal brachytherapy
- **DRUG:** concurrent capecitabine or 5-FU
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT02199236
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2024-10-29
- **Final completion:** 2024-10-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02199236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02199236, "Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02199236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*